anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 71
Group description: These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.

Exparel: Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
Eligibility criteria:
Inclusion Criteria:

Females, aged 18-45 years inclusive and ASA physical status 1-3.
Undergoing non-urgent Cesarean section with neuraxial anesthesia/analgesia.
Subjects must be physically and mentally able to participate in the study and complete all study assessments.
Subjects must be able to give fully informed consent to participate in this study after demonstrating a good understanding of the risks and benefits of the proposed components of the TAP infiltration.

Exclusion Criteria:

History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics

Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator, might preclude the potential successful performance of a bilateral TAP infiltration.
Any subject who in the opinion of the Investigator, might be harmed or be a poor candidate for participation in the study.
Any subject, who in the opinion of the Investigator, is on chronic pain medicine, including large doses of NSAIDs.
Subjects who have received any investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during their participation in this study.
Intervention: Roflumilast
Trial phase: Phase 2
ATC code: R03DX07
SMILES: O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 109
Group description: Roflumilast cream 0.3% was topically applied QD for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants legally competent to sign and give informed consent
Males and females ages 18 years and older (inclusive)
Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator
Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.
In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion Criteria:

Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed.
Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
Previous treatment with roflumilast cream or its active ingredient
Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.
Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Intervention: Roflumilast
Trial phase: Phase 2
ATC code: R03DX07
SMILES: O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: Roflumilast cream 0.15% was topically applied QD for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants legally competent to sign and give informed consent
Males and females ages 18 years and older (inclusive)
Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator
Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.
In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion Criteria:

Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed.
Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
Previous treatment with roflumilast cream or its active ingredient
Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.
Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.

Bupivacaine: Abdominal injection of bupivacaine into fascial layer.
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Undergoing elective colectomy by surgeons of Fairfax Colon and Rectal Surgery

Exclusion Criteria:

Allergic to local anesthetics
Unable to provide consent
Pregnant
On opioids at home chronically (Patients previously on a regular opioid regimen would need to be opioid-free for a period of 1 year for inclusion in the study)
Undergoing emergent operations
Undergoing loop ileostomy reversal
Undergoing abdominoperineal resection, pelvic exenteration, or perineal rectal prolapse repairs
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.

Bupivacaine liposome: Abdominal injection of bupivacaine liposome into fascial layer.
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Undergoing elective colectomy by surgeons of Fairfax Colon and Rectal Surgery

Exclusion Criteria:

Allergic to local anesthetics
Unable to provide consent
Pregnant
On opioids at home chronically (Patients previously on a regular opioid regimen would need to be opioid-free for a period of 1 year for inclusion in the study)
Undergoing emergent operations
Undergoing loop ileostomy reversal
Undergoing abdominoperineal resection, pelvic exenteration, or perineal rectal prolapse repairs
Intervention: 1-Propanol
Trial phase: Phase 4
ATC code: D08AX03 | D08AX53
SMILES: CCCO
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: Haloperidol + Promethazine + Chlorpromazine: This is the usual treatment given by this hospital during an aggressive psychiatric episode.
Eligibility criteria:
Inclusion Criteria:

Patient will be eligible if (1) requiring emergency acute intramuscular sedation because of disturbed and dangerous behaviour and (2) if the clinician is uncertain of the benefits between haloperidol plus promethazine vs haloperidol plus promethazine plus chlorpromazine.
Gender - both male and female
Age (18-64)
Clinician is unaware on the effects of either treatment interventions

Exclusion Criteria:

If the clinician KNOWS one treatment has benefit over another for a particular person
If the clinician is aware of a contra-indication of one of the treatments
If there is an Advanced Directive expressing a wish for one or other, or another treatment in the emergency setting.
If the clinician does not want to undertake for both personal and professional reasons.
If the participant is known to be allergic to one or more of the interventions
Already randomized
Already sedated
Accompanying person (Friend/Family/Police Officer) refuses patient trial entry
Intervention: Hematoporphyrin
Trial phase: Phase 4
SMILES: CC1=C(CCC(=O)O)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5C(C)O)c(C)c4C(C)O)C(C)=C3CCC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: Haloperidol + Promethazine: This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
Eligibility criteria:
Inclusion Criteria:

Patient will be eligible if (1) requiring emergency acute intramuscular sedation because of disturbed and dangerous behaviour and (2) if the clinician is uncertain of the benefits between haloperidol plus promethazine vs haloperidol plus promethazine plus chlorpromazine.
Gender - both male and female
Age (18-64)
Clinician is unaware on the effects of either treatment interventions

Exclusion Criteria:

If the clinician KNOWS one treatment has benefit over another for a particular person
If the clinician is aware of a contra-indication of one of the treatments
If there is an Advanced Directive expressing a wish for one or other, or another treatment in the emergency setting.
If the clinician does not want to undertake for both personal and professional reasons.
If the participant is known to be allergic to one or more of the interventions
Already randomized
Already sedated
Accompanying person (Friend/Family/Police Officer) refuses patient trial entry
Intervention: Sodium Thiosulfate
Trial phase: Phase 4
SMILES: O=S([O-])([O-])=S.[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 5
Group description: 50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.

Sodium Thiosulfate: A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
Eligibility criteria:
Inclusion Criteria:

Male or female adult 18 years of age or older
Must have health insurance will be eligible to participate
Must have a current diagnosis of dystrophic or idiopathic calcinosis cutis
Subjects must have at least 2 lesions of at least 2mm in size

Exclusion Criteria:

Unable to read and speak English
Allergy to any component of the sodium thiosulfate solution
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Pregnant women
Women who are breastfeeding
Prisoners
Intervention: Betamethasone Sodium Phosphate
Trial phase: Not Applicable
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 3
Group description: Topical corticosteroid is applied to the patient's lesion.

Topical corticosteroid: The topical corticosteroid will be used to treat the lesion in this study arm.
Eligibility criteria:
Inclusion Criteria:

Male or female adult 18 years of age or older
Ability to rate level of pain
Ability to rate visual satisfaction
At least 2 active lesions of CLE

Exclusion Criteria:

New or change in systemic medication for cutaneous lupus in past 6 months
Allergy to triamcinolone or betamethasone dipropionate cream
Pregnancy
Currently a prisoner
Unable to read and speak English since consent will only be available in English
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2 | Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Subjects will receive vaginal preparation with sterile saline.

Sterile saline: Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
Eligibility criteria:
Intervention Group (vaginal preparation)

Inclusion Criteria:

Pregnant women admitted for cesarean delivery
Gestational age greater than or equal to 34 weeks

Exclusion Criteria:

Rupture of membranes or active labor
Chorioamnionitis (prior to enrollment)
Recent (within 4 weeks) antibiotic exposure
Maternal HIV infection or immunocompromised state
Known allergy to shellfish, iodine, or chlorhexidine
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2 | Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 501
Group description: The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl ("normal saline") from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.

NaCl: Placebo
Eligibility criteria:
Inclusion Criteria:

In-hospital cardiac arrest
Age ≥ 18 years
Received at least one dose of adrenaline during cardiopulmonary resuscitation

Exclusion Criteria:

Clearly documented "do-not-resuscitate" order prior to the cardiac arrest
Prior enrollment in the trial
Invasive mechanical circulatory support at the time of the cardiac arrest
Known or suspected pregnancy at the time of the cardiac arrest
Intervention: Triamcinolone
Trial phase: Phase 4
ATC code: A01AC01 | C05AA12 | D07AB09 | D07BB03 | D07CB01 | D07XB02 | H02AB08 | R01AD11 | R03BA06 | S01BA05 | S02CA04
SMILES: [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 37
Group description: The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine

Triamcinolone: Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
Eligibility criteria:
Inclusion Criteria:

Newly diagnosed primary, idiopathic trigger finger(s)
Quinnell grade II or greater.
Patients must be 18 years of age or older

Exclusion Criteria:

patients taking any diabetic medications.
any history of inflammatory or autoimmune arthritis
history of prior trauma to the tendon of the affected digit
pregnancy, and breast feeding
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine

Dexamethasone: dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
Eligibility criteria:
Inclusion Criteria:

Newly diagnosed primary, idiopathic trigger finger(s)
Quinnell grade II or greater.
Patients must be 18 years of age or older

Exclusion Criteria:

patients taking any diabetic medications.
any history of inflammatory or autoimmune arthritis
history of prior trauma to the tendon of the affected digit
pregnancy, and breast feeding
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 65
Group description: Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
Eligibility criteria:
Inclusion Criteria:

ASA (American Society of Anesthesiology) class I-IV
age 81-75

Exclusion Criteria:

ASA class V
morbid obesity
patient refusal
patients with chronic pain or on pain medications
allergy to LA
patients receiving any additional regional techniques
coagulopathy
patients receiving systemic anticoagulation
local infection
procedures anticipated to last more than 5 hours.
Intervention: Guaifenesin
Trial phase: Phase 1
ATC code: R05CA03
SMILES: COc1ccccc1OCC(O)CO
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: Single Humibid® 1200 mg guaifenesin Extended-Release (ER) bi-layer tablet by mouth under fasted state
Eligibility criteria:
Inclusion Criteria:

Males and/or females between the ages of 19 and 55 years, inclusive.

Females of childbearing potential were using one of the following acceptable birth control methods:

Intrauterine device (IUD) in place for at least 3 months prior to study;
Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through 30 days beyond study completion;
Stable hormonal contraceptive for at least 3 months prior to study through 30 days beyond completion of study;

Abstinence was not an acceptable form of contraception.

Females of non-childbearing potential were surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 3 months prior to study) or postmenopausal <2 years. An FSH >40 mIU/mL was obtained and in the record.

Good general health was determined by medical history, physical examination, electrocardiogram (ECG), and clinical laboratory measures.
Within 15% of Ideal Body Weight as defined by the 1983 Metropolitan Life chart.
Non-tobacco users, who had not used nicotine or nicotine-containing products for at least 1 year.
Able to read, understand, and sign the informed consent after the nature of the study had been explained.
Negative finding on tests for Hepatitis B and C antigen as well as HIV and pregnancy test (if female).
Negative urine screen for drugs of abuse and alcohol at screening and the first check in.
Non-alcohol or drug abuser - for alcohol, defined as history of less then 4 drinks daily.

Exclusion Criteria:

Clinically significant abnormalities detected by medical history, physical, ECG, or clinical laboratory findings (as determined by the Principal Investigator). Any disease or condition which impacted absorption, distribution, metabolism, or elimination of the study drugs.
Females who were pregnant or nursing.
History of hypersensitivity reaction to the study drugs or related compounds, such as other opioids.
Receipt of an investigational drug within 1 month prior to study enrollment.
Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior study enrollment.
Known or suspected use of illicit drugs (including codeine or hydrocodone, etc.).
The use of any medication on a chronic basis with the exception of oral contraceptives for women of childbearing potential. An appropriate drug-free period for prescription or over-the-counter (OTC) drugs provided to washout any especially long half-life drugs.
Consumption of alcohol within 48 hours prior to each dosing period.
Consumption of grapefruit 14 days prior to dosing and throughout the study.
Hemoglobin value < 12 g/dL. If a subject's hemoglobin dropped below 11.0 g/dL the subject was dropped from the study at the Principal Investigator's discretion.
Intervention: Remifentanil
Trial phase: Phase 4
ATC code: N01AH06
SMILES: CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
Eligibility criteria:
Inclusion Criteria

Men and women 18- to 80-years old
ASA 1, 2, 3
1 or 2 levels ACDF

Exclusion Criteria

ASA 4
Seizure disorders
Chronic narcotic use
Opiate abuse
Major cardiac comorbidity, or significantly elevated blood pressure
Known hypersensitivity to fentanyl analogs, ketamine, or propofol injectable emulsions.
Known allergy to eggs, egg products, soybeans, or soy products
Intervention: Cholecalciferol
Trial phase: Phase 4
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: Female
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 79
Group description: Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.

Vitamin D3: Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
Eligibility criteria:
Inclusion Criteria:

Vitamin D deficient premenopausal women

Exclusion Criteria:

Pregnant women
Women during their postpartum period
Breastfeeding women
Women taking any kind of exogenous hormones
Women receiving any form of oral vitamin D replacement
Intervention: Allopurinol
Trial phase: Phase 2
ATC code: M04AA01 | M04AA51
SMILES: Oc1ncnc2[nH]ncc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)

Allopurinol: 6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
Eligibility criteria:
Inclusion Criteria:

Men and women ages 40-75 years at randomization
BMI between 25.1 and 50 kg/m2.
Type 2 diabetes diagnosed > 3 months ago. Patients with T2D will be classified based on physician diagnosis.

Exclusion Criteria:

serum uric acid < 5.5 mg/dL (for medication/allopurinol and isocaloric low-fructose diet arm)
habitual diet containing low amount of sugars < 5% of total energy intake
recent CVD event (stroke, heart failure hospitalization, revascularization or acute coronary event in the last 12 months).
abnormal thyroid tests or chronic liver disease
stage IV renal disease (GFR <30)
hyperparathyroidism
use of azathioprine
active cancer
autoimmune diseases
excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
current tobacco use
bodyweight change ≥10% within the last 6 months
history of gout or uncontrolled hypertension
A1C >10 % (only for medication/placebo arm)
Pregnancy or lactation in women (or women not using contraceptives)